MedTrace Logo

Experience of the Patient Treated With Trastuzumab (Herceptin ®) as Adjuvant for Breast Cancer

NCT01400438 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2016-07-21

No results posted yet for this study

Summary

Many studies have been devoted to the quality of life of patients during adjuvant chemotherapy for breast cancer by highlighting fatigue, psychological distress and impact on the immediate environment (spouse, children) during this difficult time for women. Curiously, no study to date has been submitted or published about how women with a one-year treatment "extra" Herceptin ® live this period in terms of quality of life, in terms of psychological impact for themselves and their families.

The investigators have no more data on how often they return to work during this treatment or on the psycho-social parameters which underpin them. It therefore seemed interesting to "give a spotlight" on this particular period in these women HER2 + by comparing a patient population of same age receiving the same adjuvant but with no Herceptin ®.

Conditions

Interventions

OTHER

questionnaires

delivery of questionnaires and self-psychological interview

OTHER

questionnaires

delivery of questionnaires and self-psychological interview

Sponsors & Collaborators

  • Centre Francois Baclesse

    lead OTHER

Principal Investigators

  • Corinne DELCAMBRE, MD · Centre François Baclesse

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2015-05-31
Completion
2015-09-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01400438 on ClinicalTrials.gov